Cargando…

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

Antibody therapy targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy induces a high rate of immune-related adverse events. The underlying factors that may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jingyu, Liu, Dai, Li, Guangfu, Staveley-O’Carroll, Kevin F., Graff, Julie N., Li, Zihai, Wu, Jennifer D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435412/ https://www.ncbi.nlm.nih.gov/pubmed/28560327 http://dx.doi.org/10.1126/sciadv.1602133

Ejemplares similares

Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma
por: Liu, Dai, et al.
Publicado: (2015)

Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity
por: Yang, Ming, et al.
Publicado: (2021)

The Important Roles of Natural Killer Cells in Liver Fibrosis
por: Yang, Ming, et al.
Publicado: (2023)

Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment
por: Yang, Ming, et al.
Publicado: (2021)

Cancer Immunotherapy and Delivery System: An Update
por: Yang, Ming, et al.
Publicado: (2022)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

The Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer
por: Tagaram, Hephzibah Rani S., et al.
Publicado: (2016)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer
por: Li, Yuanke, et al.
Publicado: (2021)

Gut microbiota mediated molecular events and therapy in liver diseases
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1/PD-L1 blockade therapy
por: Zhang, Jinyu, et al.
Publicado: (2019)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2019)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

(18)F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
por: Avella, Diego M., et al.
Publicado: (2020)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
por: Basher, Fahmin, et al.
Publicado: (2020)

Tumor-Cell–Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2020)

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol
por: Yang, Ming, et al.
Publicado: (2023)

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
por: Lesterhuis, W. Joost, et al.
Publicado: (2013)

Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2016)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
por: Zhang, Shashuang, et al.
Publicado: (2020)

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
por: Philip, Hagit, et al.
Publicado: (2021)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles
por: Esposito, Laura, et al.
Publicado: (2014)

High Levels of Soluble Ctla-4 Are Present in Anti-Mitochondrial Antibody Positive, but Not in Antibody Negative Patients with Primary Biliary Cirrhosis
por: Saverino, Daniele, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b2b4rf07j25q5526t3hms5fss1